Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
or
Menu

Novartis Ag (NVS)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (BATS)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ fieldTitles[key] ]] [[ value ]] [[ value ]]
[[ ctrl.chartTitle ]]
Full Chart

Fundamentals

See More
  • Market Capitalization, $K 204,245,040
  • Shares Outstanding, K 2,365,590
  • Annual Sales, $ 49,436 M
  • Annual Income, $ 6,712 M
  • 36-Month Beta 0.76
  • Price/Sales 4.21
  • Price/Cash Flow 18.12
  • Price/Book 3.02

Price Performance

See More
Period Period Low Period High Performance
1-Month
79.69 +8.34%
on 06/15/17
86.90 -0.64%
on 06/22/17
+5.28 (+6.51%)
since 05/23/17
3-Month
72.67 +18.81%
on 04/19/17
86.90 -0.64%
on 06/22/17
+11.91 (+16.00%)
since 03/23/17
52-Week
66.93 +29.00%
on 12/08/16
86.90 -0.64%
on 06/22/17
+5.67 (+7.03%)
since 06/23/16

Most Recent Stories

More News
OpportunityAnalyzer Report 2017: Cystic Fibrosis - Opportunity Analysis and Forecasts to 2025

Research and Markets has announced the addition of the "OpportunityAnalyzer: Cystic Fibrosis - Opportunity Analysis and Forecasts to 2025" drug pipelines to their offering. Global (7MM) sales for the...

JNJ : 136.43 (+0.28%)
VRTX : 133.50 (-1.50%)
NVS : 86.34 (unch)
RPTP : 9.00 (unch)
European Hematology Association: Global Trial of the Efficacy and Safety of CTL019 in Adult Patients with Relapsed or Refractory Diffuse Large B-cell Lymphoma: An Interim Analysis of the JULIET Study

MADRID, June 24, 2017 /PRNewswire/ --

NVS : 86.34 (unch)
European Hematology Association: Global Trial of the Efficacy and Safety of CTL019 in Adult Patients with Relapsed or Refractory Diffuse Large B-cell Lymphoma: An Interim Analysis of the JULIET Study

CTL019 consists of genetically engineered autologous T cells expressing a chimeric antigen receptor (CAR). Results from a prior single-center phase 2 study at the University of Pennsylvania showed that...

NVS : 86.34 (unch)
NEJM publishes full analysis of Rydapt® (midostaurin) Phase III RATIFY trial in newly diagnosed FLT3-mutated acute myeloid leukemia (AML)

Novartis today announced that full results from the Rydapt® (midostaurin) Phase III RATIFY (CALGB 10603 [Alliance]) clinical trial were published in The New England Journal of Medicine (NEJM)1. Top-line...

NVS : 86.34 (unch)
NEJM publishes full analysis of Rydapt(R) (midostaurin) Phase III RATIFY trial in newly diagnosed FLT3-mutated acute myeloid leukemia (AML)

Novartis International AG / NEJM publishes full analysis of Rydapt(R) (midostaurin) Phase III RATIFY trial in newly diagnosed FLT3-mutated acute myeloid leukemia (AML) . Processed and transmitted by...

NVS : 86.34 (unch)
Regeneron (REGN) Stock on Fire: What's Behind the Surge?

Shares of Regeneron Pharmaceuticals, Inc. (REGN) have moved up 14.8% over the last 30 days.

VVUS : 1.22 (+5.17%)
NVS : 86.34 (unch)
REGN : 517.33 (-1.75%)
SNY : 49.33 (-0.56%)
Pharma Stock Roundup: NVS Scores with Positive Data, Shire ADHD Drug Gets FDA Nod

All major pharma stocks were up this week with companies like Novartis (NVS) presenting positive data and others gaining FDA approval.

NVO : 44.44 (+1.76%)
MRK : 66.16 (+0.21%)
NVS : 86.34 (unch)
SHPG : 172.98 (-1.11%)
RHHBY : 32.7600 (+1.42%)
BMY : 56.64 (-1.20%)
NEOS : 7.25 (-2.03%)
Novartis Kisqali(R) (ribociclib) receives positive CHMP opinion as first-line treatment for HR+/HER2- locally advanced or metastatic breast cancer in combination with any aromatase inhibitor

Novartis International AG / Novartis Kisqali(R) (ribociclib) receives positive CHMP opinion as first-line treatment for HR+/HER2- locally advanced or metastatic breast cancer in combination with any...

NVS : 86.34 (unch)
Novartis Survey Reveals Burden of Myeloproliferative Neoplasms (Rare Blood Cancers) on Patients' Daily Activity and Ability to Work, Calling for More Proactive Symptom Assessment

CAMBERLEY, England, June 23, 2017 /PRNewswire/ --

NVS : 86.34 (unch)
Novartis Announces Half of Eligible Ph+ CML-CP Patients Remain in Treatment-free Remission (TFR) Nearly Two Years After Stopping Tasigna® (nilotinib)

CAMBERLEY, England, June 23, 2017 /PRNewswire/ --

NVS : 86.34 (unch)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 100% Buy with a Strongest short term outlook on maintaining the current direction.

Longer term, the trend strength is in the Top 1%. Long term indicators fully support a continuation of the trend.

The market is in highly overbought territory. Beware of a trend reversal.

See More

Business Summary

Novartis AG is committed to improving health and well-being through innovative products and services. The company aspires to capture and hold a leadership position in all of their businesses with a strong, sustainable performance based on continuous innovation. Their long-term success is founded on...

See More

Support & Resistance

2nd Resistance Point 87.20
1st Resistance Point 86.77
Last Price 86.34
1st Support Level 85.71
2nd Support Level 85.08

See More

Add Data Columns to this Table
Learn about our Custom Views
Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.